Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1Phase 1 1

Status

Terminated 3Recruiting 3Active not recruiting 3Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Neoplasm Metastasis 5Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Neoplasms 2Rectal Neoplasms 1Pancreatic Neoplasms 1Brain Neoplasms 1

Interventions

Bevacizumab 30pembrolizumab 29Oxaliplatin 28Leucovorin 25Fluorouracil 24Irinotecan 22Cetuximab 21Capecitabine 19Nivolumab 15Specimen Handling 12atezolizumab 11Panitumumab 10Colonoscopy 9Carboplatin 9regorafenib 8Biopsy 8trifluridine tipiracil drug combination 7Trifluridine 7Paclitaxel 7Aspirin 7balstilimab 6Standard of Care 6Cisplatin 6tislelizumab 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Immunoglobulin G 5Folfox protocol 5Disulfides 5trametinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Colorectal Neoplasms × adagrasib × Clear all
NCT04793958 2026-04-27

KRYSTAL-10

Mirati Therapeutics Inc.

Phase 3 Active not recruiting
461 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05722327 2026-03-04

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
24 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Mirati Therapeutics Inc.

Phase 1/2 Active not recruiting
731 enrolled 1 FDA
Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡